GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (NZSE:PEB) » Definitions » Institutional Ownership

Pacific Edge (NZSE:PEB) Institutional Ownership : 21.78% (As of Apr. 28, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Pacific Edge Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pacific Edge's institutional ownership is 21.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pacific Edge's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pacific Edge's Float Percentage Of Total Shares Outstanding is 0.00%.


Pacific Edge Institutional Ownership Historical Data

The historical data trend for Pacific Edge's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Edge Institutional Ownership Chart

Pacific Edge Historical Data

The historical data trend for Pacific Edge can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 23.59 23.44 23.42 22.32 21.79 21.77 21.76 21.78 21.78 21.78

Pacific Edge Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Pacific Edge Business Description

Traded in Other Exchanges
Address
87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.